Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Due to system maintenance, login and edit functionaility is currently unavailable

Ryan Bruce Corcoran, M.D.

Co-Author

This page shows the publications co-authored by Ryan Corcoran and Adriano Piris.
Connection Strength

0.306
  1. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med. 2013 Jul 31; 5(196):196ra98.
    View in: PubMed
    Score: 0.136
  2. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012 Mar; 2(3):227-35.
    View in: PubMed
    Score: 0.123
  3. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology. 2018; 7(5):e1423172.
    View in: PubMed
    Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.